Cowen Upgrades Myriad Genetics (MYGN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Myriad Genetics (MYGN) Reports Publication of GUIDED Study in Journal of Psychiatric Research
January 4, 2019 10:05 AM ESTMyriad Genetics, Inc. (NASDAQ: MYGN) today announced the publication of the landmark GeneSight GUIDED study in the Journal of Psychiatric Research. The study is the first-ever prospective, large-scale, blinded, randomized controlled trial evaluating combinatorial pharmacogenomics testing in 1,167 patients with treatment-resistant major depressive disorder who had failed at least one psychotropic medication.
The publication of the GUIDED study represents a major milestone for Myriad and a significant... More
Needham & Company Starts Myriad Genetics (MYGN) at Strong Buy
January 2, 2019 4:18 PM ESTNeedham & Company analyst Stephen Unger initiates coverage on Myriad Genetics (NASDAQ: MYGN) with a Strong Buy rating and a price target of $36.00.
The analyst commented, "We believe Myriad Genetics has significant potential for ongoing EPS upside from an expanding portfolio of molecular... More
